Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of Candidate Genes for Canine and Human Glioma

ABSTRACT: Genome-Wide Association Mapping of Canine Glioma Followed by Targeted Massive Parallel Sequencing Identifies CAMKK2, P2RX7 and DENR as Novel Candidate Genes for Canine and Human Glioma

PROVIDER: PRJEB10641 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR996251.fastq.gz	Fastqsanger.gz
	ERR996252.fastq.gz	Fastqsanger.gz
	ERR996253.fastq.gz	Fastqsanger.gz
	ERR996254.fastq.gz	Fastqsanger.gz
	ERR996255.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Effect of hypoxia on canine glioma stem-like cells metabolism

Project description:To investigate the role of hypoxia treatment on the metabolic profiles of canine glioma cells We then performed reduce representation bisulfite sequencing on 3 unique canine cell lines and correlated with functional assays

2024-03-01 | GSE223852 | GEO

Polysomes from DENR knockdown cells

Project description:The aim was to identify transcripts that are poorly translated upon knockdown of DENR. Lysates from control (GFP) and DENR knockdown S2 cells were run on polysome gradients. RNA from the (80S peak + polysome peaks) was isolated and analyzed by microarrays. In parallel, total RNA from the cells was also profiled as a normalization control and profiled. The 'translation score' of translated mRNA to total RNA was then calculated for control and DENR knockdown cells. Two biological replicates for DENR knockdown and GFP knockdown were performed. For each sample, (80S+polysomes) and total RNA were profiled, leading to 8 samples in total.

2014-06-30 | E-GEOD-54625 | biostudies-arrayexpress

Canine

Project description:Canine

| PRJNA687522 | ENA

Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma [array]

Project description:Targeting PRMT5 in canine lymphoma: we characterized expression patterns of PRMT5 in canine lymphomas and correlated these with histological subtypes using tissue microarrays. We characterized expression of PRMT5 in three canine lymphoma-derived cell lines and primary lymph node biopsies. We have demonstrated that inhibition of PRMT5 leads to growth suppression and induction of apoptosis in canine lymphoma cell lines and primary canine lymphoma cells in a time and dose-dependent manner, while selectively decreasing global marks of symmetric dimethylarginine (SDMA) and histone H4 arginine 3 symmetric di-methylation. We performed ATAC-sequencing with pathway enrichment analysis to characterize genome-wide changes in chromatin accessibility after PRMT5 inhibition. We performed gene expression microarrays with pathway analysis to characterize whole transcriptome changes in canine lymphoma cell lines treated with PRMT5 inhibitors. This work validates PRMT5 as a promising therapeutic target for canine lymphoma and supports the continued used of the spontaneously occurring canine lymphoma model for the preclinical development of PRMT5 inhibitors for the treatment of human NHL.

2021-04-20 | GSE155599 | GEO

Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma [ATAC-seq]

2021-04-20 | GSE156084 | GEO

Gene expression data of canine osteosarcoma primary tumors (Affymetrix Canine 2.0 array)

Project description:The recently developed COXEN method (PMID: 17666531) has been used to successfully extrapolate gene signatures of drug sensitivity across different tumor histotypes. We wanted to explore the utility of COXEN to predict chemosensitivity in canine cancer, specifically if we could extrapolate gene signatures identified in human datasets over to canine osteosarcoma tumors. This dataset of canine osteosarcoma tumor samples has available clinical outcome data after patients had infected limbs amputated and were treated with doxorubicin and/or carboplatin. We performed microarray analysis on this panel of tumor samples for validating our COXEN prediction models for doxorubicin or carboplatin sensitivity. Chemotherapy naive primary tumors were collected at the time of amputation and archived at the Flint Animal Cancer Center. RNA was extracted from 33 frozen archived tumor samples, followed by microarray analysis. The gene expression data was RMA preprocessed, scaled and were used as a independent test set to evaluate developed prediction models of sensitivity to doxorubicin or carboplatin. Drug predictions were than compared to clinical outcome in these patients that received doxorubicin and/or carboplatin.

2015-12-18 | E-GEOD-76127 | biostudies-arrayexpress

Polysomes from DENR knockdown cells

2014-06-30 | GSE54625 | GEO

CCOGC canine Osteosarcoma tumor samples

Project description:RNA-Seq of canine osteosarcoma tumor samples obtained from Canine Comparative Oncology and Genomics Consortium

2023-08-07 | GSE239948 | GEO

Canine Metagenome

Project description:Canine Metagenome

| PRJNA649283 | ENA

Canine tumors

Project description:Canine tumors

| PRJNA376373 | ENA